improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent
enable assignment of assess rights; (b) the allocation and use of privileged access rights should be restricted and controlled; (c) the allocation of passwords should be controlled through a formal
assess rights; (b) the allocation and use of privileged access rights should be restricted and controlled; (c) the allocation of passwords should be controlled through a formal management process; (d
processes, including effectively controlled in maintenance cost. Net gain (loss) on exchange rate Q1-2020 Q1-2019 THB Mn THB Mn THB Mn % Net gain (loss) on exchange rate 112.2 (28.3) 140.5 N.A. (>100) Change
Bt41,108mn in 2017 following controlled investment and the negotiation with suppliers for longer payment term. Also, AIS has paid license installments totaling Bt20,536mn to the NBTC. As a result, free cash
decreased by -8.4% YoY. 9M23 EBITDA increased by 4.2% YoY as a result of an improvement in core service revenue and well- controlled SG&A. The net profit closed at Bt22,084mn, surging 18% YoY driven by
manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international standards ISO 9001:2008, GMP, PICS, HACCP และ HALAL. Presently, At-Ze
located in Muang district, Chachoengsao province and authorized manufacturing cosmeceuticals and modern medicine from FDA and controlled quality and operational efficiency which certified by international